Anika Therapeutics, Inc. (ANIK) Net margin 2016–2025
Anika Therapeutics, Inc. (ANIK) net profit margin by fiscal year — reported net income divided by reported revenue.
-9.6%FY2025 · since FY2016: 31.5% → -9.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -9.6% | +37.4 pp |
| FY2024 | -47.0% | +21.4 pp |
| FY2023 | -68.4% | -55.4 pp |
| FY2022 | -13.1% | -15.9 pp |
| FY2021 | 2.8% | +21.2 pp |
| FY2020 | -18.4% | -42.1 pp |
| FY2019 | 23.7% | +6.0 pp |
| FY2018 | 17.7% | -10.3 pp |
| FY2017 | 28.1% | -3.4 pp |
| FY2016 | 31.5% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More ANIK financial trends
ANIK RevenueANIK Net incomeANIK Gross profitANIK Gross marginANIK Operating incomeANIK Operating marginANIK Operating cash flowANIK Free cash flowANIK Capital expendituresANIK Return on equityANIK Stock buybacksANIK Dividends paidANIK Total assetsANIK Total liabilitiesANIK Shareholders’ equityANIK overview →